1. Common variation in GPC5 is associated with acquired nephrotic syndrome
- Author
-
Hodaka Suzuki, Tsuyoshi Watanabe, Katsushi Tokunaga, Akihiko Mabuchi, Shiro Maeda, Atsushi Takahashi, Eisei Noiri, Toshiro Fujita, Koji Okamoto, Yusuke Nakamura, Michiaki Kubo, Nao Nishida, Kent Doi, and Tetsuo Katoh
- Subjects
Adult ,Male ,Nephrotic Syndrome ,Nephrosis ,Genome-wide association study ,Disease ,Biology ,Polymorphism, Single Nucleotide ,Podocyte ,Mice ,Glypicans ,Genetics ,medicine ,Animals ,Humans ,RNA, Messenger ,RNA, Small Interfering ,Congenital nephrotic syndrome ,Aged ,DNA Primers ,Proteinuria ,Base Sequence ,Models, Genetic ,Podocytes ,Case-control study ,Middle Aged ,medicine.disease ,Disease Models, Animal ,medicine.anatomical_structure ,Case-Control Studies ,Gene Knockdown Techniques ,Immunology ,Female ,medicine.symptom ,Nephrotic syndrome ,Genome-Wide Association Study - Abstract
Severe proteinuria is a defining factor of nephrotic syndrome irrespective of the etiology. Investigation of congenital nephrotic syndrome has shown that dysfunction of glomerular epithelial cells (podocytes) plays a crucial role in this disease. Acquired nephrotic syndrome is also assumed to be associated with podocyte injury. Here we identify an association between variants in GPC5, encoding glypican-5, and acquired nephrotic syndrome through a genome-wide association study and replication analysis (P value under a recessive model (P(rec)) = 6.0 × 10(-11), odds ratio = 2.54). We show that GPC5 is expressed in podocytes and that the risk genotype is associated with higher expression. We further show that podocyte-specific knockdown and systemic short interfering RNA injection confers resistance to podocyte injury in mouse models of nephrosis. This study identifies GPC5 as a new susceptibility gene for nephrotic syndrome and implicates GPC5 as a promising therapeutic target for reducing podocyte vulnerability in glomerular disease.
- Published
- 2011
- Full Text
- View/download PDF